Novartis: eye drug Beovu gets EU approval
(CercleFinance.com) - Novartis said that it has won a green light from the European Commission for Beovu, an injection for the treatment of wet age-related macular degeneration (AMD).
Beovu targets the excess of VEGF, a protein that promotes the growth of abnormal blood vessels underneath the retina.
AMD, a chronic, degenerative eye disease, can cause severe vision loss and blindness in people over age 65. An estimated 1.7 million people are affected by the disease in the EU.
Copyright (c) 2020 CercleFinance.com. All rights reserved.